Biocartis’ Idylla EGFR Mutation Test has secured the EU Technical Documentation Assessment and Quality Management System certificate, making it the first Idylla Test to achieve Class C companion ...
"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
The FINANCIAL — Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of ...
According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer. Certain features may make patients ...
Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line osimertinib ...
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
Review of NICE Diagnostics Guidance No. DG9; EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer: review decision Decision to move the existing guidance ...
In this retrospective study, researchers explored whether reducing osimertinib dose in EGFR-mutated metastatic NSCLC patients who experienced adverse events would worsen survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results